
AI-generated summary
Coupang Inc has been recording losses for three consecutive quarters since a personal information leak incident at the end of last year, and its combined operating profit over the three years from 2023 to 2025 was KRW 1.8987 trillion.
Coupang Inc Chairman Kim Beom-seok said that the poor performance in the third quarter was due to a temporary cost burden, and maintained the existing forecast that the margins of the product commerce division will be close to the pre-accident level next year.
In a conference call held after the third quarter performance announcement on the 3rd (local time), Chairman Kim cited factors affecting product commerce margins as supply chain disruptions, fixed cost burden due to delayed demand recovery, and increased marketing costs to bring back lost customers.
“None of these items are structural issues,” he said. “Some are short-term investments chosen by the company and others are temporary headwinds.”
Chairman Kim predicted that when supply recovers, supply chain disruptions will normalize, volume-based cost reduction effects, and logistics facility operation rates will improve. He added that marketing costs have already begun to decrease.
Coupang Inc's sales in the third quarter of this year were KRW 14.2209 trillion, an 11% increase compared to the same period last year, but it recorded an operating loss of KRW 642.3 billion, recording a deficit for three consecutive quarters since the personal information leak incident at the end of last year.
The cumulative operating loss in the first to third quarters of this year is KRW 1.8318 trillion, which is close to the combined operating profit (KRW 1.8987 trillion) for the three years from 2023 to 2025, when Coupang Inc recorded an annual surplus.
Chairman Kim announced that in the long term, he will increase the level of customer service through process improvement and automation of the logistics network while lowering service costs.
This quarter, the company also announced that it has begun work to reduce manual scanning by introducing artificial intelligence (AI) cameras to packaging workstations.
AI outlook — possibilities, not facts
Product commerce margins next year will be close to the level before the personal information leak incident.
Possible · Within months

Coupang Inc. Chairman Kim Beom-seok said that although the company recorded an operating loss of KRW 642.3 billion in the third quarter, making a deficit for three consecutive quarters, this was due to temporary cost burden and short-term investment rather than structural problems, and predicted that product commerce margins next year will be close to the level before the personal information leak incident.

Hanwha Investment & Securities raised Jeju Air's target stock price from 6,500 won to 7,500 won in accordance with its forecast for next year's operating profit growth. Jeju Air turned a profit in the third quarter with an operating profit of 54.9 billion won, and the previous day's closing price was 5,720 won.

Daishin Securities lowered its target stock price from 530,000 won to 500,000 won, reflecting lower forecasts for North American battery shipments and small battery profitability, despite LG Energy Solutions' performance improvement forecast for next year. There is room for an increase of about 48% compared to the previous day's closing price.

KB Securities lowered Poongsan's target stock price from 112,000 won to 90,000 won and maintained its investment opinion of 'buy'. It is expected that the new copper sector will slow down due to the unfavorable macro environment, such as the strong won and the stabilization of copper price declines, and the recovery of delivery dates in the defense industry will be delayed to 2027.

Kakao Bank achieved its highest performance ever, recording a cumulative net profit of 469.8 billion won in the third quarter. Net profit in the third quarter increased 27.2% to KRW 141.7 billion, and the number of customers reached 27.94 million, an influx of 1.7 million over the year.

Celltrion announced that it plans to confirm the weight loss effect of CT-G32/SCO-940, a quadruple action obesity treatment candidate, in non-clinical trials and submit a clinical trial plan to the US FDA in February next year.